Article citationsMore>>

Nagai, T., Arao, T., Furuta, K., Sakai, K., Kudo, K., Kaneda, H., et al. (2011) Sorafenib Inhibits the Hepatocyte Growth Factor-Mediated Epithelial Mesenchymal Transition in Hepatocellular Carcinoma. Molecular Cancer Therapeutics, 10, 169-177.
https://doi.org/10.1158/1535-7163.MCT-10-0544

has been cited by the following article:

• TITLE: Predictors of Recurrence of Hepatocellular Carcinoma after Transarterial Chemoembolization: Role of Hepatocyte Growth Factor

  AUTHORS: Amr Mohamed Zaghloul, Ahmed Sedky, Ali Hussein Mohammed, Samer A. El-Sawy, Ahmed Abd El Rady Ahmed, Emad Eldin Nabil

  KEYWORDS: Hepatocellular Carcinoma, Hepatocyte Growth Factor, Prediction of HCC Recurrence

  JOURNAL NAME: Open Journal of Gastroenterology, Vol.10 No.6, June 15, 2020

  ABSTRACT: Background: Hepatocellular carcinoma is the third leading cause of tumor related mortality and develops mostly in patients with chronic liver disease and liver cirrhosis. Human hepatocyte growth factor (HGF) is produced in various organs of the body and is characterized as a multifunctional factor with various biologic activities. Aim: Our aim was to investigate the predictive factors of recurrence specially the role of HGF in patients with HCC treated with TACE. Patients and Methods: one hundred HCC patients treated by TACE who achieved complete response were included and divided into two groups according to disease free survival (DFS) status at 1 year: the non-early recurrence (NER) group (1) and the early recurrence (ER) group (2). Univariate binary logistic regression analysis for the possible risk factors of recurrence showed that AFP, multinodularity and HGF level were significant. Conclusion: high AFP, multinodularity and high HGF were inter-related possible risk factors for 1-year recurrence of HCC in patients with initial remission following TACE.